nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—Chlorphenesin—CYP19A1—esophageal cancer	0.00736	0.375	CrCbGaD
Betaxolol—Chlorphenesin—PTGS2—esophageal cancer	0.00338	0.172	CrCbGaD
Betaxolol—Eye pain—Capecitabine—esophageal cancer	0.00304	0.00422	CcSEcCtD
Betaxolol—Hyperuricaemia—Methotrexate—esophageal cancer	0.00303	0.00422	CcSEcCtD
Betaxolol—Libido decreased—Capecitabine—esophageal cancer	0.00296	0.00411	CcSEcCtD
Betaxolol—Increased appetite—Capecitabine—esophageal cancer	0.00292	0.00406	CcSEcCtD
Betaxolol—Amnesia—Capecitabine—esophageal cancer	0.00292	0.00406	CcSEcCtD
Betaxolol—Inflammation—Methotrexate—esophageal cancer	0.0029	0.00403	CcSEcCtD
Betaxolol—Renal impairment—Capecitabine—esophageal cancer	0.00288	0.00401	CcSEcCtD
Betaxolol—Thirst—Capecitabine—esophageal cancer	0.00288	0.00401	CcSEcCtD
Betaxolol—Atenolol—ABCB1—esophageal cancer	0.00288	0.146	CrCbGaD
Betaxolol—Respiratory failure—Methotrexate—esophageal cancer	0.00286	0.00398	CcSEcCtD
Betaxolol—Blood uric acid increased—Methotrexate—esophageal cancer	0.00286	0.00398	CcSEcCtD
Betaxolol—Purpura—Capecitabine—esophageal cancer	0.00284	0.00396	CcSEcCtD
Betaxolol—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00283	0.00393	CcSEcCtD
Betaxolol—Arthritis—Capecitabine—esophageal cancer	0.00282	0.00392	CcSEcCtD
Betaxolol—Myocardial infarction—Cisplatin—esophageal cancer	0.00281	0.00391	CcSEcCtD
Betaxolol—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00281	0.00391	CcSEcCtD
Betaxolol—Cardiac failure—Capecitabine—esophageal cancer	0.00281	0.00391	CcSEcCtD
Betaxolol—Lethargy—Capecitabine—esophageal cancer	0.0028	0.00389	CcSEcCtD
Betaxolol—Stomatitis—Cisplatin—esophageal cancer	0.00279	0.00389	CcSEcCtD
Betaxolol—Conjunctivitis—Cisplatin—esophageal cancer	0.00279	0.00388	CcSEcCtD
Betaxolol—Cystitis noninfective—Methotrexate—esophageal cancer	0.00275	0.00382	CcSEcCtD
Betaxolol—Osteoarthritis—Capecitabine—esophageal cancer	0.00274	0.00381	CcSEcCtD
Betaxolol—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00272	0.00378	CcSEcCtD
Betaxolol—Cystitis—Methotrexate—esophageal cancer	0.00271	0.00378	CcSEcCtD
Betaxolol—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00271	0.00378	CcSEcCtD
Betaxolol—Acebutolol—ABCB1—esophageal cancer	0.00265	0.135	CrCbGaD
Betaxolol—Bradycardia—Cisplatin—esophageal cancer	0.00262	0.00364	CcSEcCtD
Betaxolol—Mood swings—Capecitabine—esophageal cancer	0.0026	0.00361	CcSEcCtD
Betaxolol—Ataxia—Capecitabine—esophageal cancer	0.00258	0.00359	CcSEcCtD
Betaxolol—Mouth ulceration—Methotrexate—esophageal cancer	0.00254	0.00354	CcSEcCtD
Betaxolol—Bladder pain—Methotrexate—esophageal cancer	0.00254	0.00354	CcSEcCtD
Betaxolol—Hypokalaemia—Capecitabine—esophageal cancer	0.00249	0.00347	CcSEcCtD
Betaxolol—Visual impairment—Cisplatin—esophageal cancer	0.00248	0.00345	CcSEcCtD
Betaxolol—Breast disorder—Capecitabine—esophageal cancer	0.00248	0.00345	CcSEcCtD
Betaxolol—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00247	0.00343	CcSEcCtD
Betaxolol—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00247	0.00343	CcSEcCtD
Betaxolol—Nasopharyngitis—Capecitabine—esophageal cancer	0.00245	0.00341	CcSEcCtD
Betaxolol—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00242	0.00336	CcSEcCtD
Betaxolol—Eye disorder—Cisplatin—esophageal cancer	0.0024	0.00334	CcSEcCtD
Betaxolol—Tinnitus—Cisplatin—esophageal cancer	0.0024	0.00334	CcSEcCtD
Betaxolol—Lymphadenopathy—Methotrexate—esophageal cancer	0.00239	0.00333	CcSEcCtD
Betaxolol—Flushing—Cisplatin—esophageal cancer	0.00239	0.00332	CcSEcCtD
Betaxolol—Cardiac disorder—Cisplatin—esophageal cancer	0.00239	0.00332	CcSEcCtD
Betaxolol—Dysphagia—Capecitabine—esophageal cancer	0.00237	0.0033	CcSEcCtD
Betaxolol—Asthma—Capecitabine—esophageal cancer	0.00237	0.0033	CcSEcCtD
Betaxolol—Influenza—Capecitabine—esophageal cancer	0.00237	0.0033	CcSEcCtD
Betaxolol—Thrombophlebitis—Methotrexate—esophageal cancer	0.00236	0.00328	CcSEcCtD
Betaxolol—Diabetes mellitus—Methotrexate—esophageal cancer	0.00235	0.00326	CcSEcCtD
Betaxolol—Bronchospasm—Capecitabine—esophageal cancer	0.00233	0.00324	CcSEcCtD
Betaxolol—Immune system disorder—Cisplatin—esophageal cancer	0.00232	0.00323	CcSEcCtD
Betaxolol—Mediastinal disorder—Cisplatin—esophageal cancer	0.00232	0.00323	CcSEcCtD
Betaxolol—Angina pectoris—Capecitabine—esophageal cancer	0.00231	0.00321	CcSEcCtD
Betaxolol—Arrhythmia—Cisplatin—esophageal cancer	0.0023	0.0032	CcSEcCtD
Betaxolol—Bronchitis—Capecitabine—esophageal cancer	0.00228	0.00317	CcSEcCtD
Betaxolol—Alopecia—Cisplatin—esophageal cancer	0.00227	0.00316	CcSEcCtD
Betaxolol—Metoprolol—ABCB1—esophageal cancer	0.00224	0.114	CrCbGaD
Betaxolol—Malnutrition—Cisplatin—esophageal cancer	0.00224	0.00312	CcSEcCtD
Betaxolol—Erythema—Cisplatin—esophageal cancer	0.00224	0.00312	CcSEcCtD
Betaxolol—Dysuria—Capecitabine—esophageal cancer	0.00222	0.00308	CcSEcCtD
Betaxolol—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.0022	0.00306	CcSEcCtD
Betaxolol—Weight increased—Capecitabine—esophageal cancer	0.00216	0.003	CcSEcCtD
Betaxolol—Muscle spasms—Cisplatin—esophageal cancer	0.00215	0.003	CcSEcCtD
Betaxolol—Weight decreased—Capecitabine—esophageal cancer	0.00214	0.00298	CcSEcCtD
Betaxolol—Hyperglycaemia—Capecitabine—esophageal cancer	0.00214	0.00297	CcSEcCtD
Betaxolol—Pneumonia—Capecitabine—esophageal cancer	0.00212	0.00296	CcSEcCtD
Betaxolol—Infestation—Capecitabine—esophageal cancer	0.00211	0.00294	CcSEcCtD
Betaxolol—Infestation NOS—Capecitabine—esophageal cancer	0.00211	0.00294	CcSEcCtD
Betaxolol—Vision blurred—Cisplatin—esophageal cancer	0.00211	0.00294	CcSEcCtD
Betaxolol—Depression—Capecitabine—esophageal cancer	0.00211	0.00293	CcSEcCtD
Betaxolol—Tremor—Cisplatin—esophageal cancer	0.0021	0.00292	CcSEcCtD
Betaxolol—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00208	0.0029	CcSEcCtD
Betaxolol—Lethargy—Methotrexate—esophageal cancer	0.00208	0.0029	CcSEcCtD
Betaxolol—Ill-defined disorder—Cisplatin—esophageal cancer	0.00208	0.00289	CcSEcCtD
Betaxolol—Myocardial infarction—Capecitabine—esophageal cancer	0.00207	0.00288	CcSEcCtD
Betaxolol—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00207	0.00288	CcSEcCtD
Betaxolol—Anaemia—Cisplatin—esophageal cancer	0.00207	0.00288	CcSEcCtD
Betaxolol—Stomatitis—Capecitabine—esophageal cancer	0.00206	0.00286	CcSEcCtD
Betaxolol—Conjunctivitis—Capecitabine—esophageal cancer	0.00205	0.00286	CcSEcCtD
Betaxolol—Osteoarthritis—Methotrexate—esophageal cancer	0.00204	0.00284	CcSEcCtD
Betaxolol—Malaise—Cisplatin—esophageal cancer	0.00202	0.00281	CcSEcCtD
Betaxolol—Epistaxis—Capecitabine—esophageal cancer	0.00199	0.00277	CcSEcCtD
Betaxolol—Agranulocytosis—Capecitabine—esophageal cancer	0.00197	0.00274	CcSEcCtD
Betaxolol—Mood swings—Methotrexate—esophageal cancer	0.00193	0.00269	CcSEcCtD
Betaxolol—Bradycardia—Capecitabine—esophageal cancer	0.00193	0.00269	CcSEcCtD
Betaxolol—Ataxia—Methotrexate—esophageal cancer	0.00192	0.00267	CcSEcCtD
Betaxolol—Myalgia—Cisplatin—esophageal cancer	0.00191	0.00265	CcSEcCtD
Betaxolol—Rhinitis—Capecitabine—esophageal cancer	0.0019	0.00264	CcSEcCtD
Betaxolol—Anxiety—Cisplatin—esophageal cancer	0.0019	0.00264	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00189	0.00263	CcSEcCtD
Betaxolol—Hypoaesthesia—Capecitabine—esophageal cancer	0.00189	0.00262	CcSEcCtD
Betaxolol—Discomfort—Cisplatin—esophageal cancer	0.00188	0.00262	CcSEcCtD
Betaxolol—Pharyngitis—Capecitabine—esophageal cancer	0.00188	0.00262	CcSEcCtD
Betaxolol—Breast disorder—Methotrexate—esophageal cancer	0.00184	0.00257	CcSEcCtD
Betaxolol—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00184	0.00256	CcSEcCtD
Betaxolol—Oedema—Cisplatin—esophageal cancer	0.00183	0.00254	CcSEcCtD
Betaxolol—Visual impairment—Capecitabine—esophageal cancer	0.00183	0.00254	CcSEcCtD
Betaxolol—Infection—Cisplatin—esophageal cancer	0.00182	0.00253	CcSEcCtD
Betaxolol—Nervous system disorder—Cisplatin—esophageal cancer	0.00179	0.00249	CcSEcCtD
Betaxolol—Thrombocytopenia—Cisplatin—esophageal cancer	0.00179	0.00249	CcSEcCtD
Betaxolol—Tachycardia—Cisplatin—esophageal cancer	0.00178	0.00248	CcSEcCtD
Betaxolol—Skin disorder—Cisplatin—esophageal cancer	0.00178	0.00247	CcSEcCtD
Betaxolol—Eye disorder—Capecitabine—esophageal cancer	0.00177	0.00247	CcSEcCtD
Betaxolol—Tinnitus—Capecitabine—esophageal cancer	0.00177	0.00246	CcSEcCtD
Betaxolol—Hyperhidrosis—Cisplatin—esophageal cancer	0.00177	0.00246	CcSEcCtD
Betaxolol—Asthma—Methotrexate—esophageal cancer	0.00176	0.00245	CcSEcCtD
Betaxolol—Flushing—Capecitabine—esophageal cancer	0.00176	0.00245	CcSEcCtD
Betaxolol—Cardiac disorder—Capecitabine—esophageal cancer	0.00176	0.00245	CcSEcCtD
Betaxolol—Anorexia—Cisplatin—esophageal cancer	0.00174	0.00242	CcSEcCtD
Betaxolol—Angiopathy—Capecitabine—esophageal cancer	0.00172	0.00239	CcSEcCtD
Betaxolol—Immune system disorder—Capecitabine—esophageal cancer	0.00171	0.00238	CcSEcCtD
Betaxolol—Mediastinal disorder—Capecitabine—esophageal cancer	0.00171	0.00238	CcSEcCtD
Betaxolol—Hypotension—Cisplatin—esophageal cancer	0.00171	0.00238	CcSEcCtD
Betaxolol—Chills—Capecitabine—esophageal cancer	0.0017	0.00237	CcSEcCtD
Betaxolol—Arrhythmia—Capecitabine—esophageal cancer	0.00169	0.00236	CcSEcCtD
Betaxolol—Alopecia—Capecitabine—esophageal cancer	0.00168	0.00233	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00167	0.00232	CcSEcCtD
Betaxolol—Mental disorder—Capecitabine—esophageal cancer	0.00166	0.00231	CcSEcCtD
Betaxolol—Erythema—Capecitabine—esophageal cancer	0.00165	0.0023	CcSEcCtD
Betaxolol—Malnutrition—Capecitabine—esophageal cancer	0.00165	0.0023	CcSEcCtD
Betaxolol—Dysuria—Methotrexate—esophageal cancer	0.00165	0.00229	CcSEcCtD
Betaxolol—Paraesthesia—Cisplatin—esophageal cancer	0.00164	0.00228	CcSEcCtD
Betaxolol—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00164	0.00228	CcSEcCtD
Betaxolol—Dyspnoea—Cisplatin—esophageal cancer	0.00163	0.00227	CcSEcCtD
Betaxolol—Erectile dysfunction—Methotrexate—esophageal cancer	0.00162	0.00226	CcSEcCtD
Betaxolol—Dysgeusia—Capecitabine—esophageal cancer	0.00162	0.00225	CcSEcCtD
Betaxolol—Decreased appetite—Cisplatin—esophageal cancer	0.00159	0.00221	CcSEcCtD
Betaxolol—Muscle spasms—Capecitabine—esophageal cancer	0.00159	0.00221	CcSEcCtD
Betaxolol—Pneumonia—Methotrexate—esophageal cancer	0.00158	0.0022	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00158	0.0022	CcSEcCtD
Betaxolol—Infestation NOS—Methotrexate—esophageal cancer	0.00157	0.00219	CcSEcCtD
Betaxolol—Infestation—Methotrexate—esophageal cancer	0.00157	0.00219	CcSEcCtD
Betaxolol—Depression—Methotrexate—esophageal cancer	0.00157	0.00218	CcSEcCtD
Betaxolol—Pain—Cisplatin—esophageal cancer	0.00156	0.00217	CcSEcCtD
Betaxolol—Vision blurred—Capecitabine—esophageal cancer	0.00156	0.00216	CcSEcCtD
Betaxolol—Tremor—Capecitabine—esophageal cancer	0.00155	0.00215	CcSEcCtD
Betaxolol—Stomatitis—Methotrexate—esophageal cancer	0.00153	0.00213	CcSEcCtD
Betaxolol—Ill-defined disorder—Capecitabine—esophageal cancer	0.00153	0.00213	CcSEcCtD
Betaxolol—Conjunctivitis—Methotrexate—esophageal cancer	0.00153	0.00213	CcSEcCtD
Betaxolol—Anaemia—Capecitabine—esophageal cancer	0.00153	0.00212	CcSEcCtD
Betaxolol—Sweating—Methotrexate—esophageal cancer	0.00151	0.0021	CcSEcCtD
Betaxolol—Feeling abnormal—Cisplatin—esophageal cancer	0.00151	0.0021	CcSEcCtD
Betaxolol—Malaise—Capecitabine—esophageal cancer	0.00149	0.00207	CcSEcCtD
Betaxolol—Epistaxis—Methotrexate—esophageal cancer	0.00148	0.00206	CcSEcCtD
Betaxolol—Vertigo—Capecitabine—esophageal cancer	0.00148	0.00206	CcSEcCtD
Betaxolol—Syncope—Capecitabine—esophageal cancer	0.00148	0.00206	CcSEcCtD
Betaxolol—Agranulocytosis—Methotrexate—esophageal cancer	0.00147	0.00204	CcSEcCtD
Betaxolol—Palpitations—Capecitabine—esophageal cancer	0.00146	0.00203	CcSEcCtD
Betaxolol—Loss of consciousness—Capecitabine—esophageal cancer	0.00145	0.00202	CcSEcCtD
Betaxolol—Body temperature increased—Cisplatin—esophageal cancer	0.00144	0.00201	CcSEcCtD
Betaxolol—Cough—Capecitabine—esophageal cancer	0.00144	0.002	CcSEcCtD
Betaxolol—Myalgia—Capecitabine—esophageal cancer	0.00141	0.00196	CcSEcCtD
Betaxolol—Chest pain—Capecitabine—esophageal cancer	0.00141	0.00196	CcSEcCtD
Betaxolol—Arthralgia—Capecitabine—esophageal cancer	0.00141	0.00196	CcSEcCtD
Betaxolol—Pharyngitis—Methotrexate—esophageal cancer	0.0014	0.00195	CcSEcCtD
Betaxolol—Anxiety—Capecitabine—esophageal cancer	0.0014	0.00195	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.0014	0.00194	CcSEcCtD
Betaxolol—Discomfort—Capecitabine—esophageal cancer	0.00139	0.00193	CcSEcCtD
Betaxolol—Dry mouth—Capecitabine—esophageal cancer	0.00137	0.00191	CcSEcCtD
Betaxolol—Visual impairment—Methotrexate—esophageal cancer	0.00136	0.00189	CcSEcCtD
Betaxolol—Confusional state—Capecitabine—esophageal cancer	0.00136	0.00189	CcSEcCtD
Betaxolol—Oedema—Capecitabine—esophageal cancer	0.00135	0.00187	CcSEcCtD
Betaxolol—Hypersensitivity—Cisplatin—esophageal cancer	0.00135	0.00187	CcSEcCtD
Betaxolol—Infection—Capecitabine—esophageal cancer	0.00134	0.00186	CcSEcCtD
Betaxolol—Shock—Capecitabine—esophageal cancer	0.00133	0.00184	CcSEcCtD
Betaxolol—Nervous system disorder—Capecitabine—esophageal cancer	0.00132	0.00184	CcSEcCtD
Betaxolol—Eye disorder—Methotrexate—esophageal cancer	0.00132	0.00184	CcSEcCtD
Betaxolol—Thrombocytopenia—Capecitabine—esophageal cancer	0.00132	0.00184	CcSEcCtD
Betaxolol—Tinnitus—Methotrexate—esophageal cancer	0.00132	0.00183	CcSEcCtD
Betaxolol—Tachycardia—Capecitabine—esophageal cancer	0.00131	0.00183	CcSEcCtD
Betaxolol—Asthenia—Cisplatin—esophageal cancer	0.00131	0.00182	CcSEcCtD
Betaxolol—Cardiac disorder—Methotrexate—esophageal cancer	0.00131	0.00182	CcSEcCtD
Betaxolol—Skin disorder—Capecitabine—esophageal cancer	0.00131	0.00182	CcSEcCtD
Betaxolol—Hyperhidrosis—Capecitabine—esophageal cancer	0.0013	0.00181	CcSEcCtD
Betaxolol—Anorexia—Capecitabine—esophageal cancer	0.00128	0.00179	CcSEcCtD
Betaxolol—Angiopathy—Methotrexate—esophageal cancer	0.00128	0.00178	CcSEcCtD
Betaxolol—Immune system disorder—Methotrexate—esophageal cancer	0.00128	0.00177	CcSEcCtD
Betaxolol—Mediastinal disorder—Methotrexate—esophageal cancer	0.00127	0.00177	CcSEcCtD
Betaxolol—Chills—Methotrexate—esophageal cancer	0.00127	0.00176	CcSEcCtD
Betaxolol—Hypotension—Capecitabine—esophageal cancer	0.00126	0.00175	CcSEcCtD
Betaxolol—Diarrhoea—Cisplatin—esophageal cancer	0.00125	0.00174	CcSEcCtD
Betaxolol—Alopecia—Methotrexate—esophageal cancer	0.00125	0.00174	CcSEcCtD
Betaxolol—Mental disorder—Methotrexate—esophageal cancer	0.00124	0.00172	CcSEcCtD
Betaxolol—Malnutrition—Methotrexate—esophageal cancer	0.00123	0.00171	CcSEcCtD
Betaxolol—Erythema—Methotrexate—esophageal cancer	0.00123	0.00171	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00123	0.00171	CcSEcCtD
Betaxolol—Insomnia—Capecitabine—esophageal cancer	0.00122	0.0017	CcSEcCtD
Betaxolol—Paraesthesia—Capecitabine—esophageal cancer	0.00121	0.00168	CcSEcCtD
Betaxolol—Dysgeusia—Methotrexate—esophageal cancer	0.0012	0.00167	CcSEcCtD
Betaxolol—Dyspnoea—Capecitabine—esophageal cancer	0.0012	0.00167	CcSEcCtD
Betaxolol—Dyspepsia—Capecitabine—esophageal cancer	0.00119	0.00165	CcSEcCtD
Betaxolol—Decreased appetite—Capecitabine—esophageal cancer	0.00117	0.00163	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00116	0.00162	CcSEcCtD
Betaxolol—Vomiting—Cisplatin—esophageal cancer	0.00116	0.00162	CcSEcCtD
Betaxolol—Fatigue—Capecitabine—esophageal cancer	0.00116	0.00162	CcSEcCtD
Betaxolol—Vision blurred—Methotrexate—esophageal cancer	0.00116	0.00161	CcSEcCtD
Betaxolol—Rash—Cisplatin—esophageal cancer	0.00115	0.0016	CcSEcCtD
Betaxolol—Constipation—Capecitabine—esophageal cancer	0.00115	0.0016	CcSEcCtD
Betaxolol—Pain—Capecitabine—esophageal cancer	0.00115	0.0016	CcSEcCtD
Betaxolol—Dermatitis—Cisplatin—esophageal cancer	0.00115	0.0016	CcSEcCtD
Betaxolol—Ill-defined disorder—Methotrexate—esophageal cancer	0.00114	0.00159	CcSEcCtD
Betaxolol—Anaemia—Methotrexate—esophageal cancer	0.00114	0.00158	CcSEcCtD
Betaxolol—Propranolol—ABCB1—esophageal cancer	0.00113	0.0576	CrCbGaD
Betaxolol—Feeling abnormal—Capecitabine—esophageal cancer	0.00111	0.00154	CcSEcCtD
Betaxolol—Malaise—Methotrexate—esophageal cancer	0.00111	0.00154	CcSEcCtD
Betaxolol—Vertigo—Methotrexate—esophageal cancer	0.0011	0.00154	CcSEcCtD
Betaxolol—Nausea—Cisplatin—esophageal cancer	0.00109	0.00151	CcSEcCtD
Betaxolol—Cough—Methotrexate—esophageal cancer	0.00107	0.00149	CcSEcCtD
Betaxolol—Urticaria—Capecitabine—esophageal cancer	0.00107	0.00149	CcSEcCtD
Betaxolol—Body temperature increased—Capecitabine—esophageal cancer	0.00107	0.00148	CcSEcCtD
Betaxolol—Arthralgia—Methotrexate—esophageal cancer	0.00105	0.00146	CcSEcCtD
Betaxolol—Chest pain—Methotrexate—esophageal cancer	0.00105	0.00146	CcSEcCtD
Betaxolol—Myalgia—Methotrexate—esophageal cancer	0.00105	0.00146	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00104	0.00145	CcSEcCtD
Betaxolol—Discomfort—Methotrexate—esophageal cancer	0.00103	0.00144	CcSEcCtD
Betaxolol—Confusional state—Methotrexate—esophageal cancer	0.00101	0.00141	CcSEcCtD
Betaxolol—Infection—Methotrexate—esophageal cancer	0.000996	0.00139	CcSEcCtD
Betaxolol—Hypersensitivity—Capecitabine—esophageal cancer	0.000993	0.00138	CcSEcCtD
Betaxolol—Nervous system disorder—Methotrexate—esophageal cancer	0.000984	0.00137	CcSEcCtD
Betaxolol—Thrombocytopenia—Methotrexate—esophageal cancer	0.000982	0.00137	CcSEcCtD
Betaxolol—Skin disorder—Methotrexate—esophageal cancer	0.000974	0.00136	CcSEcCtD
Betaxolol—Hyperhidrosis—Methotrexate—esophageal cancer	0.00097	0.00135	CcSEcCtD
Betaxolol—Asthenia—Capecitabine—esophageal cancer	0.000967	0.00134	CcSEcCtD
Betaxolol—Anorexia—Methotrexate—esophageal cancer	0.000956	0.00133	CcSEcCtD
Betaxolol—Pruritus—Capecitabine—esophageal cancer	0.000953	0.00133	CcSEcCtD
Betaxolol—Hypotension—Methotrexate—esophageal cancer	0.000937	0.0013	CcSEcCtD
Betaxolol—Diarrhoea—Capecitabine—esophageal cancer	0.000922	0.00128	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000914	0.00127	CcSEcCtD
Betaxolol—Insomnia—Methotrexate—esophageal cancer	0.000907	0.00126	CcSEcCtD
Betaxolol—Paraesthesia—Methotrexate—esophageal cancer	0.000901	0.00125	CcSEcCtD
Betaxolol—Dyspnoea—Methotrexate—esophageal cancer	0.000894	0.00124	CcSEcCtD
Betaxolol—Dizziness—Capecitabine—esophageal cancer	0.000891	0.00124	CcSEcCtD
Betaxolol—Dyspepsia—Methotrexate—esophageal cancer	0.000883	0.00123	CcSEcCtD
Betaxolol—Decreased appetite—Methotrexate—esophageal cancer	0.000872	0.00121	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000866	0.0012	CcSEcCtD
Betaxolol—Fatigue—Methotrexate—esophageal cancer	0.000865	0.0012	CcSEcCtD
Betaxolol—Pain—Methotrexate—esophageal cancer	0.000858	0.00119	CcSEcCtD
Betaxolol—Vomiting—Capecitabine—esophageal cancer	0.000857	0.00119	CcSEcCtD
Betaxolol—Rash—Capecitabine—esophageal cancer	0.000849	0.00118	CcSEcCtD
Betaxolol—Dermatitis—Capecitabine—esophageal cancer	0.000849	0.00118	CcSEcCtD
Betaxolol—Headache—Capecitabine—esophageal cancer	0.000844	0.00117	CcSEcCtD
Betaxolol—Feeling abnormal—Methotrexate—esophageal cancer	0.000827	0.00115	CcSEcCtD
Betaxolol—Nausea—Capecitabine—esophageal cancer	0.0008	0.00111	CcSEcCtD
Betaxolol—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.0008	0.00306	CbGpPWpGaD
Betaxolol—Urticaria—Methotrexate—esophageal cancer	0.000797	0.00111	CcSEcCtD
Betaxolol—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.000796	0.00304	CbGpPWpGaD
Betaxolol—Body temperature increased—Methotrexate—esophageal cancer	0.000793	0.0011	CcSEcCtD
Betaxolol—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.000793	0.00303	CbGpPWpGaD
Betaxolol—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000775	0.00297	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.000763	0.00292	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000752	0.00288	CbGpPWpGaD
Betaxolol—Hypersensitivity—Methotrexate—esophageal cancer	0.000739	0.00103	CcSEcCtD
Betaxolol—Asthenia—Methotrexate—esophageal cancer	0.00072	0.001	CcSEcCtD
Betaxolol—Pruritus—Methotrexate—esophageal cancer	0.00071	0.000987	CcSEcCtD
Betaxolol—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.000709	0.00271	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.000699	0.00267	CbGpPWpGaD
Betaxolol—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000699	0.00267	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.000695	0.00266	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000687	0.00263	CbGpPWpGaD
Betaxolol—Diarrhoea—Methotrexate—esophageal cancer	0.000686	0.000955	CcSEcCtD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000672	0.00257	CbGpPWpGaD
Betaxolol—Dizziness—Methotrexate—esophageal cancer	0.000663	0.000923	CcSEcCtD
Betaxolol—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000657	0.00251	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.000646	0.00247	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000639	0.00244	CbGpPWpGaD
Betaxolol—Vomiting—Methotrexate—esophageal cancer	0.000638	0.000887	CcSEcCtD
Betaxolol—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000637	0.00244	CbGpPWpGaD
Betaxolol—Rash—Methotrexate—esophageal cancer	0.000632	0.00088	CcSEcCtD
Betaxolol—Dermatitis—Methotrexate—esophageal cancer	0.000632	0.000879	CcSEcCtD
Betaxolol—Headache—Methotrexate—esophageal cancer	0.000628	0.000874	CcSEcCtD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000625	0.00239	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000622	0.00238	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000608	0.00232	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000606	0.00232	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000601	0.0023	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000599	0.00229	CbGpPWpGaD
Betaxolol—Nausea—Methotrexate—esophageal cancer	0.000596	0.000829	CcSEcCtD
Betaxolol—ADRB1—GPCR ligand binding—GNG7—esophageal cancer	0.000594	0.00227	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000593	0.00227	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000592	0.00227	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000586	0.00224	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000585	0.00224	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—GNG7—esophageal cancer	0.000581	0.00222	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000578	0.00221	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.00055	0.0021	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000544	0.00208	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.000544	0.00208	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000532	0.00203	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—CXCL2—esophageal cancer	0.000523	0.002	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000515	0.00197	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—CXCL2—esophageal cancer	0.000512	0.00196	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GDI2—esophageal cancer	0.000499	0.00191	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.00049	0.00187	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GDI2—esophageal cancer	0.000488	0.00186	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—ANXA1—esophageal cancer	0.000487	0.00186	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.00048	0.00184	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—ANXA1—esophageal cancer	0.000476	0.00182	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—SST—esophageal cancer	0.000473	0.00181	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.000466	0.00178	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—SST—esophageal cancer	0.000463	0.00177	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—GHRL—esophageal cancer	0.000461	0.00176	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.00046	0.00176	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—GHRL—esophageal cancer	0.000451	0.00173	CbGpPWpGaD
Betaxolol—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000449	0.00172	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000438	0.00168	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.000437	0.00167	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000432	0.00165	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.00042	0.00161	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000412	0.00158	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000406	0.00155	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.0004	0.00153	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.0004	0.00153	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—AKAP13—esophageal cancer	0.000386	0.00148	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—AKAP13—esophageal cancer	0.000377	0.00144	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	0.000371	0.00142	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000366	0.0014	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KMT2D—esophageal cancer	0.00036	0.00138	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000358	0.00137	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000353	0.00135	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KMT2D—esophageal cancer	0.000353	0.00135	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—AKAP13—esophageal cancer	0.00035	0.00134	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	0.000349	0.00133	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000348	0.00133	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PDE4D—esophageal cancer	0.000345	0.00132	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000344	0.00132	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—AKAP13—esophageal cancer	0.000343	0.00131	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000341	0.0013	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000341	0.0013	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—GNG7—esophageal cancer	0.000336	0.00128	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—GNG7—esophageal cancer	0.000328	0.00126	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000321	0.00123	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PDE4D—esophageal cancer	0.00032	0.00123	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ADCYAP1—esophageal cancer	0.000314	0.0012	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PDE4D—esophageal cancer	0.000314	0.0012	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—GNG7—esophageal cancer	0.000305	0.00117	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—GNG7—esophageal cancer	0.000298	0.00114	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000296	0.00113	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—WWOX—esophageal cancer	0.000294	0.00112	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—CXCL2—esophageal cancer	0.000289	0.00111	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—WWOX—esophageal cancer	0.000287	0.0011	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FKBP1A—esophageal cancer	0.000279	0.00107	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000275	0.00105	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FKBP1A—esophageal cancer	0.000273	0.00105	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—WIF1—esophageal cancer	0.000273	0.00104	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—ANXA1—esophageal cancer	0.000269	0.00103	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CXCL2—esophageal cancer	0.000269	0.00103	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—SST—esophageal cancer	0.000267	0.00102	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—WIF1—esophageal cancer	0.000267	0.00102	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CXCL2—esophageal cancer	0.000263	0.001	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—SST—esophageal cancer	0.000262	0.001	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—GHRL—esophageal cancer	0.000261	0.000997	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—GHRL—esophageal cancer	0.000255	0.000975	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000252	0.000964	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—ANXA1—esophageal cancer	0.00025	0.000955	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000247	0.000943	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—ANXA1—esophageal cancer	0.000244	0.000934	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—SST—esophageal cancer	0.000243	0.000929	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000242	0.000925	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—SST—esophageal cancer	0.000238	0.000909	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—GHRL—esophageal cancer	0.000237	0.000905	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PFN1—esophageal cancer	0.000236	0.000902	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—GHRL—esophageal cancer	0.000232	0.000885	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PFN1—esophageal cancer	0.000231	0.000882	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000221	0.000846	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000221	0.000846	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ELMO1—esophageal cancer	0.000212	0.00081	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000211	0.000807	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ELMO1—esophageal cancer	0.000207	0.000792	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—AKAP13—esophageal cancer	0.000207	0.000792	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—AKAP13—esophageal cancer	0.000202	0.000774	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000191	0.00073	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PDE4D—esophageal cancer	0.000189	0.000724	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CA1—esophageal cancer	0.000188	0.00072	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000188	0.00072	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.000188	0.000717	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.000188	0.000717	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000187	0.000715	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PDE4D—esophageal cancer	0.000185	0.000708	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GNG7—esophageal cancer	0.00018	0.000689	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GNG7—esophageal cancer	0.000176	0.000674	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CA2—esophageal cancer	0.000172	0.000658	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—XIAP—esophageal cancer	0.000169	0.000645	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000168	0.000641	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—XIAP—esophageal cancer	0.000165	0.000631	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.00016	0.000612	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ADH7—esophageal cancer	0.00016	0.000612	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CTNNA1—esophageal cancer	0.00016	0.00061	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CA1—esophageal cancer	0.000159	0.00061	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.000159	0.00061	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CXCL2—esophageal cancer	0.000159	0.000607	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CTNNA1—esophageal cancer	0.000156	0.000597	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CXCL2—esophageal cancer	0.000155	0.000593	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PSME2—esophageal cancer	0.000148	0.000567	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PSME1—esophageal cancer	0.000148	0.000567	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ANXA1—esophageal cancer	0.000147	0.000564	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CA2—esophageal cancer	0.000146	0.000558	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PSME1—esophageal cancer	0.000145	0.000554	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PSME2—esophageal cancer	0.000145	0.000554	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ANXA1—esophageal cancer	0.000144	0.000552	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SST—esophageal cancer	0.000143	0.000549	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000143	0.000545	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SST—esophageal cancer	0.00014	0.000537	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.00014	0.000537	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GHRL—esophageal cancer	0.00014	0.000535	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOTCH3—esophageal cancer	0.00014	0.000535	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FBXW7—esophageal cancer	0.000138	0.000526	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOTCH3—esophageal cancer	0.000137	0.000523	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GHRL—esophageal cancer	0.000137	0.000523	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ADH7—esophageal cancer	0.000136	0.000518	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PLCE1—esophageal cancer	0.000136	0.000518	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FBXW7—esophageal cancer	0.000135	0.000515	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000134	0.000513	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000134	0.000512	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.00013	0.000499	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000127	0.000486	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOTCH2—esophageal cancer	0.000125	0.00048	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	0.000123	0.000469	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000121	0.000464	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000121	0.000464	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ADH1B—esophageal cancer	0.000119	0.000455	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000116	0.000445	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TYMP—esophageal cancer	0.000114	0.000434	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000112	0.000428	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	0.000111	0.000425	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000111	0.000424	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP26A1—esophageal cancer	0.000111	0.000423	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	0.000109	0.000416	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALOX15—esophageal cancer	0.000108	0.000412	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000106	0.000403	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	0.000105	0.000403	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	0.000103	0.000394	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTO1—esophageal cancer	0.000103	0.000393	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TPI1—esophageal cancer	0.000103	0.000393	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALDH2—esophageal cancer	9.89e-05	0.000378	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALDOB—esophageal cancer	9.85e-05	0.000377	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GAPDH—esophageal cancer	9.48e-05	0.000363	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTT1—esophageal cancer	9.4e-05	0.00036	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CRABP1—esophageal cancer	9.4e-05	0.000359	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP2A6—esophageal cancer	9.3e-05	0.000355	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GNG7—esophageal cancer	8.94e-05	0.000342	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ENO1—esophageal cancer	8.81e-05	0.000337	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTGS1—esophageal cancer	8.81e-05	0.000337	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PSME1—esophageal cancer	8.68e-05	0.000332	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PSME2—esophageal cancer	8.68e-05	0.000332	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	8.62e-05	0.00033	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	8.43e-05	0.000322	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALDH2—esophageal cancer	8.38e-05	0.00032	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KDR—esophageal cancer	8.24e-05	0.000315	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KDR—esophageal cancer	8.06e-05	0.000308	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTT1—esophageal cancer	7.97e-05	0.000305	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP2A6—esophageal cancer	7.87e-05	0.000301	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.84e-05	0.0003	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	7.76e-05	0.000297	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	7.59e-05	0.00029	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	7.49e-05	0.000286	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ENO1—esophageal cancer	7.46e-05	0.000285	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTGS1—esophageal cancer	7.46e-05	0.000285	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PSME2—esophageal cancer	7.36e-05	0.000281	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PSME1—esophageal cancer	7.36e-05	0.000281	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	7.04e-05	0.000269	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	7.04e-05	0.000269	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	6.92e-05	0.000264	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	6.89e-05	0.000263	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	6.77e-05	0.000259	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	6.61e-05	0.000253	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	6.47e-05	0.000247	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HMOX1—esophageal cancer	6.43e-05	0.000246	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.42e-05	0.000246	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP1B1—esophageal cancer	6.35e-05	0.000243	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOS3—esophageal cancer	6.3e-05	0.000241	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ABCB1—esophageal cancer	6.17e-05	0.000236	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	6.16e-05	0.000236	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	6e-05	0.00023	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP19A1—esophageal cancer	5.97e-05	0.000228	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	5.89e-05	0.000225	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	5.87e-05	0.000225	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	5.77e-05	0.00022	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HMOX1—esophageal cancer	5.45e-05	0.000208	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.34e-05	0.000204	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ABCB1—esophageal cancer	5.23e-05	0.0002	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCND1—esophageal cancer	5.21e-05	0.000199	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	5.09e-05	0.000195	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	5.04e-05	0.000193	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	4.93e-05	0.000188	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EP300—esophageal cancer	4.79e-05	0.000183	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EP300—esophageal cancer	4.69e-05	0.000179	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MYC—esophageal cancer	4.18e-05	0.00016	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CREBBP—esophageal cancer	4.12e-05	0.000158	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MYC—esophageal cancer	4.09e-05	0.000156	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EGFR—esophageal cancer	4.09e-05	0.000156	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	4e-05	0.000153	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.95e-05	0.000151	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NOS3—esophageal cancer	3.69e-05	0.000141	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	3.55e-05	0.000136	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.49e-05	0.000134	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	3.47e-05	0.000133	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TP53—esophageal cancer	3.43e-05	0.000131	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.38e-05	0.000129	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TP53—esophageal cancer	3.36e-05	0.000128	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NOS3—esophageal cancer	3.13e-05	0.00012	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.86e-05	0.000109	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—EP300—esophageal cancer	2.81e-05	0.000107	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—EP300—esophageal cancer	2.38e-05	9.1e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.08e-05	7.94e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.76e-05	6.73e-05	CbGpPWpGaD
